Posted by Michael Wonder on 08 Aug 2018
FDA approves treatment for two rare types of non-Hodgkin lymphoma
8 August 2018 - The U.S. FDA today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
This approval provides a new treatment option for patients with mycosis fungoides (MS) and is the first FDA approval of a drug specifically for Sézary syndrome (SS).
The approval was based on a clinical trial of 372 patients with relapsed MF or SS who received either Poteligeo or a type of chemotherapy called vorinostat. Progression-free survival (the amount of time a patient stays alive without the cancer growing) was longer for patients taking Poteligeo (median 7.6 months) compared to patients taking vorinostat (median 3.1 months).
